Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Fingolimod-A sphingosine-like molecule inhibits vesicle mobility and secretion in astrocytes.
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.
Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.
Dopaminergic Modulation of CD4+CD25 Regulatory T Lymphocytes in Multiple Sclerosis Patients during Interferon-β Therapy.
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
Higher Relative Risk for Multiple Sclerosis in a Pediatric and Adolescent Diabetes Population: Analysis From DPV Data Base.
Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with MS.
Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial.
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
Effect of met-enkephalin on chromosomal aberrations in the lymphocytes of the peripheral blood of patients with multiple sclerosis.
LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex.
The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade.
An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.
New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.
Synthesis and biological evaluation of new 1,2-dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure-activity relationship.
Expression and activation by epstein barr virus of human endogenous retroviruses-w in blood cells and astrocytes: inference for multiple sclerosis.
Double blind placebo-controlled Phase I/II clinical trial of idebenone in patients with primary progressive multiple sclerosis (IPPoMS)
Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod.
The Many Facets of Cell Injury: Angiogenesis to Autophagy.
Severe anemia in a patient with multiple sclerosis treated with natalizumab.
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
Artielle Immunotherapeutics Announces Positive Results of Phase ! Multiple Sclerosis Trial

Pages